Search hospitals
>
Connecticut
>
New Haven
Yale University
Claim this profile
New Haven, Connecticut 06510
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Solid Tumors
Conducts research for Pancreatic Cancer
1112 reported clinical trials
192 medical researchers
Summary
Yale University is a medical facility located in New Haven, Connecticut. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Solid Tumors, Pancreatic Cancer and other specialties. Yale University is involved with conducting 1,112 clinical trials across 1,745 conditions. There are 192 research doctors associated with this hospital, such as Nina S. Kadan-Lottick, Farzana Pashankar, Patricia M Lorusso, and Alessandro Santin.
Area of expertise
Cancer
Yale University has run 135 trials for Cancer. Some of their research focus areas include:
Breast Cancer
Yale University has run 93 trials for Breast Cancer. Some of their research focus areas include:
Top PIs
Nina S. Kadan-Lottick
MedStar Georgetown University Hospital
8 years of reported clinical research
Farzana Pashankar
Yale University
8 years of reported clinical research
Patricia M Lorusso
Yale Cancer Center
7 years of reported clinical research
Alessandro Santin
Smilow Cancer Hospital at Yale New Haven
6 years of reported clinical research
Clinical Trials running at Yale University
Breast Cancer
Skin Cancer
Lung Cancer
Multiple Myeloma
Breast cancer
Pancreatic Cancer
Ovarian Cancer
Testicular cancer
Neuroblastoma
Small Cell Lung Cancer
Sacituzumab Tirumotecan + Pembrolizumab
for Breast Cancer
Researchers want to know if sacituzumab tirumotecan given alone or with pembrolizumab can treat triple negative breast cancer (TNBC). The main goal of this study is to learn if people treated with sacituzumab tirumotecan alone or with pembrolizumab live longer overall or without the cancer growing or spreading compared to people treated with chemotherapy.
Recruiting
2 awards
Phase 3
3 criteria
PF-07248144 + Fulvestrant
for Breast Cancer
The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. HR-positive breast cancer cells have proteins on their surface called receptors that bind to hormones like estrogen and progesterone (female sex hormones). These hormones can promote the growth of cancer cells. HER2-negative describes cells that have a small amount or none of a protein called HER2 on their surface. In normal cells, HER2 helps control cell growth. Cancer cells that are HER2-negative may grow more slowly and are less likely to recur (come back) or spread to other parts of the body than cancer cells that have a large amount of HER2 on their surface. Advanced cancer is a term that is often used to describe cancer that is unlikely to be cured. Metastatic cancer is the type where the cancer cells spread from one part of the body to another. This study is seeking for participants whose breast cancer has gotten worsen after receiving cyclin dependent kinase (CDK) 4/6 inhibitor-based therapy. Half of participants in this study will receive their usual study treatment, everolimus with endocrine therapy (either exemestane or fulvestrant) for HR-positive/HER2-negative advanced or metastatic breast cancer (A/mBC). The study doctor will discuss which hormone therapy is right for the participant before treatment begins. PF-07248144 is a tablet that will be taken by mouth at home every day in a 28-day cycle. Fulvestrant will be given as two injections (one injection in the buttock) at visits to the study clinic. Everolimus and exemestane are also tablets and will be taken by mouth at home every day in a 28-day cycle. The study will compare the experiences of people receiving PF-07248144 in combination with fulvestrant to those of the people who do not. This will help see if PF-07248144 in combination with fulvestrant is safe and effective.
Recruiting
2 awards
Phase 3
4 criteria
Imlunestrant
for Early Breast Cancer
This trial is testing a new medication called imlunestrant to see if it works better than standard hormone treatments for certain breast cancer patients. The study focuses on patients with early-stage breast cancer that is estrogen receptor positive and HER2 negative, who have already been on hormone therapy for a period of time and are at high risk of their cancer returning. Imlunestrant works by blocking estrogen from helping cancer cells grow.
Recruiting
2 awards
Phase 3
6 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Yale University?
Yale University is a medical facility located in New Haven, Connecticut. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Solid Tumors, Pancreatic Cancer and other specialties. Yale University is involved with conducting 1,112 clinical trials across 1,745 conditions. There are 192 research doctors associated with this hospital, such as Nina S. Kadan-Lottick, Farzana Pashankar, Patricia M Lorusso, and Alessandro Santin.
Where is Yale University located?
To reach Yale New Haven Hospital, take Exit 57 to Route 34 east into New Haven, turn right onto Ella T. Grasso Boulevard (Rte. 10), and then left onto South Frontage Road, following the hospital signs. For GPS or online mapping, use 35 Park Street, New Haven, CT 06519.
Who should I call to ask about financial aid or insurance network?
For financial assistance at Yale University hospitals, contact the Billing and Finance Department at 866-341-0673 or visit their website for assistance with bills, coordination of benefits, and premium payments. For specific programs and eligibility, visit the YNHHS Financial Assistance Programs and Eligibility Guidelines page. For billing inquiries or insurance-related questions, call 855-547-4584 or visit the Billing FAQs or Contact Us pages.
What insurance does Yale University accept?
Yale University and its affiliated hospitals, including Yale New Haven Health System, accept a wide range of insurance plans. Coverage varies for individuals at the university, such as students, faculty, and staff. Yale Medicine and Yale New Haven Health System hospitals participate with numerous insurance carriers, including but not limited to Aetna, Anthem, Cigna, ConnectiCare, Medicaid, Medicare, UnitedHealthcare, and TRICARE. It is crucial to confirm with your insurance provider that your desired doctor or healthcare provider is within your network, as exceptions may exist.
What awards or recognition has Yale University received?
Yale New Haven Hospital, in collaboration with Yale University and University College London, focuses on advancing biomedical research and healthcare worldwide. It ranks among the top U.S. hospitals, with national rankings in 11 of 16 specialties such as diabetes and endocrinology, psychiatry, gastroenterology and GI surgery, and gynecology. The hospital is also lauded for its dedication to teaching and clinical research, earning the Joint Commission's Gold Seal of Approval for Advanced Certification for Total Hip and Knee Replacement.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.